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Context: The widespread use of T therapy, particularly in aging males, necessitates knowledge of
the relationship between T and the cardiovascular system.
Evidence Acquisition: The review is based on a 1970 to 2013 PubMed search with terms related to
androgens in combination with cardiovascular disease, including T, dihydrotestosterone, trial,
mortality, cardiovascular disease,myocardial infarction, blood pressure, endothelial function, dys-
lipidemia, thrombosis, ventricular function, and arrhythmia. Original articles, systematic reviews
and meta-analyses, and relevant citations were screened.
Evidence Synthesis: Low T has been linked to increased blood pressure, dyslipidemia, atheroscle-
rosis, arrhythmia, thrombosis, endothelial dysfunction, as well as to impaired left ventricular func-
tion. On the one hand, amodest association is suggested between low endogenous T and incident
cardiovascular disease or cardiovascular mortality, implying unrecognized beneficial T effects,
residual confounding, or a relationship with health status. On the other hand, treatments with T
to restore “normal concentrations” have so far not been proven to be beneficial with respect to
cardiovascular disease; neither have they definitely shown specific adverse cardiovascular effects.
The cardiovascular risk-benefit profile of T therapy remains largely evasive in view of a lack of
well-designed and adequately powered randomized clinical trials.
Conclusions: The important knowledge gap as to the exact relationship between T and cardio-
vascular diseasewould support a cautious, restrainedapproach toT therapy in agingmen, pending
clarification of benefits and risks by adequately powered clinical trials of sufficient duration. (J Clin
Endocrinol Metab 98: 4300–4310, 2013)
Observational studies of associations between endog-enous androgens and cardiovascular disease (CVD)
are most often of cross-sectional design not allowing in-
ference on causal relationships, whereas interpretation of
available prospective cohort studies is hampered by insuf-
ficient possibilities to exclude residual confounding of risk
for cardiovascular events. Clearly, use of T therapy that is
beneficial, or at least safe, should be based both on a thor-
ough understanding of the relationship between endoge-
nous androgens and CVD in conditions of health and dis-
ease and on findings of controlled trials with relevant
endpoints, with appropriate design, and of sufficient du-
ration.Unfortunately, experimental evidence forpotential
beneficial or adverse effects of T on the cardiovascular
system is rather limited. First of all, there are no published
reports on randomized clinical trialswith the primary goal
to evaluate T effects on incident cardiovascular events.
Furthermore, many of the T trials were conducted in dis-
eased men, such as men with alcoholic cirrhosis (1),
chronic renal disease on dialysis (2), rheumatoid arthritis
(3), cognitive decline (4), malnutrition (5), frailty (6, 7),
coronary artery disease (8), heart failure (9), metabolic
syndrome or type 2 diabetes (10, 11), thereby limiting
interpretation and generalization of results. A small num-
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ber of T trials have been performed in men who suffered
solely from hypogonadism (12–16). However, in almost
every study in diseased and/or hypogonadal men, charac-
terization of the baseline cardiovascular risk profile and
methodology to establish the incidence of cardiovascular
events were generally poor.
The present narrative review aims to summarize pres-
ent knowledge and to identify ways to increase the insight
into potential beneficial and adverse effects of T on the
cardiovascular system in men.
Physiological Action of T on the
Cardiovascular System
The Leydig cells in the testes produce most of T in the
circulation, with minor contribution from precursor an-
drogens secreted by the adrenal cortices. Most T in the
circulation (97–99%) is bound to plasma proteins, ie,
tightlybound toSHBGandwith lower affinity toalbumin.
Free T and at least part of the hormone loosely bound to
albumin, together referred to as bioavailable T, are
thought to freely diffuse into target cells and bind to the
androgen receptor (AR) either directly or after 5-reduc-
tion to dihydrotestosterone (17). SHBG-bound Tmay en-
ter the cell by endocytosis (18). The contribution of free vs
total T to final androgen effects is controversial.However,
in a recent meta-analysis, the magnitude of effect size of
free vs total T and CVD endpoints was robustly similar
(19). Androgens display predominantly genomic effects,
but there is also evidence for nongenomic effects, which
contribute to considerable variation in duration of andro-
gen actions (20).
Genomic effects involve binding of T or dihydrotestos-
terone to the AR andmigration of the androgen-AR com-
plex to the cell nucleus, where it induces transcription of
specific segments ofDNA.ARsareubiquitously expressed
in nearly all mammalian tissues, including cells from the
cardiovascular system, like vascular smooth muscle and
endothelial cells, myocardial fibers, macrophages, and
platelets. The general mechanism of action and clinical
implications of alterations in expression and degradation
of the AR have been extensively reviewed by Lee and
Chang (21). In addition to ligand binding, transcriptional
activity of theAR is affected by coregulators that influence
a number of functional properties of the AR, including
ligand selectivity and DNA binding capacity, reviewed by
Heinlein and Chang (22).
Furthermore, a functional polyglutamine tract poly-
morphism in the AR, encoded by a CAG triplet repeat in
exon 1 of the AR gene, can influence the strength of the
transcriptional response with a longer tract associated
with lower AR activity (23). Interestingly, one study re-
ported that a low number of CAG repeats is associated
with lower levels of high-density lipoprotein cholesterol
and reduced endothelial response to ischemia, both
known risk factors for coronary heart disease (CHD) (24).
The nongenomic effects of androgens are rapid as com-
pared to the genomic effects and include the activation of
kinase-signaling cascades and modulation of intracellular
calcium levels, as reviewed extensively by Heinlein and
Chang (25).
Finally and importantly, T is a prohormone because it
is converted by the enzyme 5-reductase to dihydrotes-
tosterone, and T also exerts indirect effects through acti-
vation of estrogen receptors, after aromatization into es-
tradiol by the aromatase (P450a) enzyme. Although both
T and estradiol impact on the cardiovascular system (26,
27), the degree of conversion of T into estradiol might be
important with respect to the balance between beneficial
and adverse effects, as will be further discussed. The re-
lationship between circulating androgens and clinical ef-
fects is further complicated by the potential for occurrence
of 5-reduction and/or aromatization locally in cardio-
vascular target tissues.
Androgens and Cardiovascular Risk
Factors
Blood pressure
Epidemiological findings show that endogenous T and
blood pressure are inversely correlated. Low T might be
predictive of hypertension in aging males, but it is not
established whether hypertension is the cause or conse-
quence of low T (28). However, T treatment had no effect
on blood pressure in hypogonadal males with type 2 di-
abetes or the metabolic syndrome (10) and resulted in a
borderline significant increase in hypogonadal and older
men (15). Dihydrotestosterone slightly decreased systolic
blood pressure (borderline significantly) in healthy men
(29). Studies in ratmodels provide a potential explanation
for this complexity by showing that genetic background
might determine prohypertensive effects of T. One study
found that smooth muscle cells derived from rats with a
genetic predisposition to arterial hypertension showed an
increased responsiveness to T (30, 31). Another study
showed that T supplements significantly increased mean
arterial pressure in obese, but not in lean,Zucker rats (32),
despite increased proteinuria and accelerated renal injury
in the latter (32). The authors therefore suggested careful
monitoring of blood pressure and renal integrity after
treatment of obese men with chronic T supplements (32).
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Endothelial progenitor cells and endothelial
function
Cardiovascular health is dependent on angiogenesis,
which might be stimulated by androgens in a sex-specific
manner (33), and on proper endothelial healing after in-
jury. The latter process is regulated by endothelial pro-
genitor cells derived from bone-marrow cells (34). Some
studies reported the endothelial progenitor cell number to
be lower in hypogonadalmen as compared to healthy con-
trol subjects (35), and that T and dihydrotestosterone
could stimulate endothelial progenitor cells via the AR
(36, 37). However, others found no direct effects of an-
drogens on endothelial progenitor cell biology either in
vitro or in vivo (38).
Reduction of endothelium-dependent, flow-mediated
vasodilatation has been suggested to be an important pre-
dictor of atherosclerosis (39). Although some authors re-
ported an adverse effect on flow-mediated vasodilatation
by T therapy in hypogonadal men (40, 41), others sug-
gested the opposite. Long-term oral supplemental admin-
istration of T was reported to improve brachial arterial
vasoreactivity in men with coronary artery disease (42).
Furthermore, a study on intracoronary T infusion showed
coronary vasodilatation and increased coronary blood
flow inmenwith low plasma T and CHD (43). Finally, an
8-week treatment with oral T undecanoate in men with
CHDresulted indecreasedbasal arterial stiffness, possibly
by a modest positive effect on myocardial perfusion (44).
Possibly, discrepancies between studies might be ex-
plained by differences in the dose of T supplied,whichwas
supraphysiological in the study on coronary vasodilata-
tion (43).
Dyslipidemia
Obesity-associated alterations in circulating androgens
and lipids are mutually involved in the pathogenesis of
associatedmetabolic complications.Depending on the de-
gree of aromatization, androgens directly and indirectly
affect adipose tissue adaptation to the continuing expo-
sure to energy excess (45–47). The specific relationship
between sex steroids and lipid and lipoproteinmetabolism
has been extensively reviewed by Wang et al. (48). Inter-
vention studies in hypogonadal men with type 2 diabetes
and in elderlymales show that exogenousT therapyhasno
effect on lipids (7, 10, 16) or is associated with a decrease
in high-density lipoprotein cholesterol (15, 49). A recent
metabolic study on lipid oxidation and very low-density
lipoprotein-triglyceride production suggests that T is not
a major determinant of resting very low-density lipopro-
tein-triglyceride kinetics in men (50).
Thrombosis
Abuse of anabolic-androgenic steroids by athletes has
been associated with the development of myocardial in-
farction and stroke (51). T therapy may increase hemo-
globin and hematocrit (49) and may regulate the expres-
sionofplatelet thromboxaneA2receptors inhumans (52).
This may contribute to thrombogenicity. Furthermore, it
was found that the risk for stroke might be ascribed not
only to low T (53) but also to increased estradiol concen-
trations (54), especially in elderly males, who have higher
rates of aromatization (55). A recent study reported a link
between thrombotic events, like osteonecrosis of the hips,
pulmonary embolism, and amaurosis fugax, and exoge-
nous T therapy (56). The authors linked the events to
positivity for factor V Leiden mutation and other familial
and acquired thrombophilias. The report suggested that
the events were likely caused by aromatization of exoge-
nous T, an estradiol-induced thrombophilia, superim-
posed on familial thrombophilia (56, 57). Consequently,
the degree of aromatization might be a factor to take into
consideration if T treatment is considered.
Left ventricular function and myocardial infarction
In a cross-sectional observational population study of
1223 healthy middle-aged men, T appeared to associate
inversely and estradiol positively with left ventricle sys-
tolic function (58). Also, rodent studies suggest opposite
effects of T and estradiol on the heart, especially after
ischemia (59–61).Mechanistically, it hasbeen shown that
both endogenous and exogenousT decrease the activity of
the cardioprotective signal transducer and activator of
transcription (STAT3)/suppressor of cytokine signaling
(SOCS3) pathway in themyocardiumafter acute ischemia
and reperfusion (62). Importantly, this decrease in myo-
cardial STAT3 activation and SOCS3 expression is asso-
ciated with a worse outcome (62). Accordingly, the tran-
sient decrease inT, observedaftermyocardial infarction in
male patients (63), may therefore be considered as adap-
tive and limit damage to the postischemic myocardial
function. Taken together, these findings suggest that
changes in the degree of aromatization might be of signif-
icance for cardiac function and outcome after a myocar-
dial infarction.
B-type natriuretic peptide
B-type natriuretic peptide is secreted by the brain and
the heart atria and is stored mainly in cardiac ventricular
myocardium. It can cause natriuresis, diuresis, and vaso-
dilation, and it inhibits secretion of renin and aldosterone.
It has favorable effects on the heart function.
Although T was inversely associated with circulating
levels of B-type natriuretic peptide and the N-terminal
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fragment of pro-B-type natriuretic peptide (64), evalu-
ation of the Framingham cohort suggested that T was
not the primary mediator of circulating levels of these
factors (65).
Arrhythmia
Both the long QT and the short QT syndrome are as-
sociated with atrial fibrillation and sudden cardiac death
(66). Experimentalmodels show that androgens canmod-
ulate a variety of ionic currents, with the net result that
repolarization is shortened, as reviewed by James et al
(67). Cross-sectional observational studies suggest that T
levels may explain differences in QT-interval duration be-
tween men and women and could contribute to popula-
tion variability in QT-interval duration among men (68).
T therapy resulted in a direct effect of T to shorten QT
intervals in older men. However, the observed mean de-
creases were small and, according to the authors, unlikely
to affect risks of arrhythmic events in patients receiving
QT-prolongingmedications (69).Yet, a significant impact
on the interval has been shown in androgen-abusing body
builders (70). The question that remains to be addressed is
how these findings fit into the complex genetic and envi-
ronmental etiology of repolarization disturbances (71).
Androgens and Cardiovascular Events:
Evidence From Prospective Observational
Studies
A major limitation of cross-sectional studies is that they
are essentially hypothesis-generating in nature, whereas
prospective studies could provide information on causal-
ity. As detailed in Table 1, a total of 19 studies have ad-
dressed the prospective relationship between endogenous
T concentrations and cardiovascular events.
Atherosclerosis in observational studies
Six of the 19 studies evaluated the relationship between
endogenous T and progression in atherosclerosis, as as-
sessed by peripheral arterial disease (72), atherosclerosis
of the abdominal aorta (73), progression of carotid ath-
erosclerosis (74), progression of intima media thickness
(75), arterial stiffness (76), and carotid artery intima me-
dia thickness (77). These studies reported either no asso-
ciation or a weak association between low T and progres-
sionofatherosclerosis.Accordingly, ameta-analysis of the
data obtained for nearly 900menwith progression of ath-
erosclerosis could not establish a statistically significant
risk difference by endogenous T levels (1 SD) for athero-
sclerosis (19).
Incident cardiovascular events in observational
studies
Twometa-analysesbasedon the findingsofprospective
studies on T and incident CVD (19) and mortality (78)
identified an inverse association between T and incident
CVD and mortality in elderly males. The conclusions of
the meta-analyses and the earlier prospective studies (79–
86) were supported by more recent prospective studies
(87–90). Studies directed at the association betweenT and
incident myocardial infarction did not reveal a relation-
ship (79–81). Results from studies evaluating incident









of Disease Outcome Abstract Conclusions of Authors
Price, 1997 (72) 55–74 5 40 AS No support for sex hormones in the development of peripheral arterial disease
Hak, 2002 (73) 55 7 28 AS An independent inverse association between T and aortic atherosclerosis
Muller, 2004 (74) 77.2 4 195 AS Low free T was related to IMT of the common carotid artery
Eller, 2005 (75) 50 4 95 AS T was borderline significantly associated (negatively) with progression in IMT
Hougaku, 2006 (76) 68 11.8 206 AS Adverse influence of low T on the CV system in men may be mediated in part via effects of
T on vascular structure and function
Tivesten, 2006 (77) 58 3 313 AS No association between total or free T and change in IMT
Cauley, 1987 (79) 46 6–8 163 MI No relationship between sex hormones and risk of a heart attack
Philips, 1988 (80) 52–74 7 96 MI No association between sex hormones and MI
Vikan, 2009 (81) 59.6 11.2 144 MI No significant changes in risk for first-ever MI across different total or free T levels
Yeap, 2009 (53) 78.4 3.5 119 S Lower total T predicts increased incidence of S or transient ischemic attack
Yarnell, 1993 (82) 45–59 5 153 IHD No support for T as primary risk factor for IHD
Araujo, 2007 (83) 40 to 70 15.3 101 IHD Little support for the hypothesis that endogenous sex steroid levels are associated with risk of
premature death but further investigation of the relationship between sex
steroids and mortality from ischemic heart disease may be warranted
Hautanen, 1994 (84) 48 5 62 CVD T no coronary risk factor
Arnlöv, 2006 (85) 56 10 386 CVD Serum T was not statistically significantly associated with incident CVD
Khaw, 2007 (86) 40 to 79 7 293 CVD T inversely related to mortality due to CVD
Akishita, 2010 (87) 48 6 20 CVD Low T is associated with CV events
Ohlsson, 2011 (88) 69–81 5 485 CV events High T predicted a reduced risk of CV events
Menke, 2010 (89) 40 9 42 CM Low T has a higher risk of CV mortality
Hyde, 2012 (90) 70–88 5.1 207 CM Low T predicts mortality from CVD
AS, atherosclerosis measurement; IHD, ischemic heart disease; CM, cardiovascular mortality; CV, cardiovascular; MI, myocardial infarction; S,
stroke or transient ischemic attack; IMT, intima media-thickness.
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CVD, ischemic heart disease, or cardiovascular death re-
vealed more heterogeneous results (82–90). Nevertheless,
all prospective studies taken together, which report on
more than 2500 events, including incident CVD, ischemic
heart disease, myocardial infarction, stroke, and cardio-
vascular death, are suggestive of a modest association be-
tween low endogenous T and incident cardiovascular
events (Table 1).
Androgens and Cardiovascular Events:
Evidence From Studies With T Treatment
Arecentmeta-analysis on exogenousTon cardiovascular-
related events displayed a difference according to the
source of funding, with an increase in risk in studies that
were not funded by the pharmaceutical industry (91).
However, randomized clinical trialswith the primary end-
point to establish beneficial and adverse effects of T treat-
ment vs placebo on incident cardiovascular events have
not been published so far. Randomized clinical trials con-
ducted in patients with hypogonadism reported small im-
provements in sexual function, bone mineral density, and
muscle strength (7, 9), whereas randomized clinical trials
conducted in males with other underlying disorders (see
introductory section), using a variety of dosages and treat-
ment modalities, reported inconsistent results. Part of the
difference in adverse eventsmight alreadybe explainedby,
eg, treatment modalities (92). These trials varied further
with respect to duration from a few weeks to a maximum
of 36 months, and handling of the cardiovascular risk
profile at baseline and events at follow-up was generally
limited.
To gain robust insight, we selected randomized, dou-
ble-blind, placebo-controlled T trials that included more
than100participants (1, 6, 7, 10–16) (Table 2). Fiveof the
10 identified trials reported T effects on lipids (7, 10, 13,
15, 16), and four trials reported blood pressure results (6,
10, 12, 15). Overall, no statistically significant difference
between placebo and T treatment could be established, as
shownby an estimated relative risk (RR) (95%confidence
interval [CI]) of 1.64 (0.77–3.47) (all studies, Table 2,
random-effectsmodel),most likely due to a lownumberof
events in all studies together (n  69). The reported car-
diovascular events in the T-treated participants included
(in order of frequency) arrhythmia, hypertension, myo-
cardial infarction, peripheral edema, coronary artery by-















24–79 Alcoholic cirrhosis/N 28 Oral 600 mg/d 87:134 0:3, thrombosis
Snyder, 2001
(16)
65 Y 36 Transdermal patch 6 mg/d 54:54 Lipids7 1:2, myocardial infarction; 2:2, CABG;
1:3, arrhythmia; 1:2, vascular events
Emmelot-Vonk,
2008 (15)
60–80 Y 6 Oral TU 160 mg/d 110:113 2 HDL;1BP (P  .08) 3:7, cardiovascular complaints
Legros, 2009
(14)
50 Y 12 Oral TU 80, 160,
240 mg/d
79:237 0:2, arrhythmia, cardiac arrest
Srinivas-Shankar,
2010 (7)
 65 Frailty/Y 6 Transdermal gel 50 mg/d 132:130 Lipids7 1:0, myocardial infarction; 1:1, abdominal
aneurysm; 0:2, pulmonary embolism,
heart failure
Basaria, 2010 (6) 65 Limitations in mobility/Y 6 Transdermal gel 100 mg/d 103:106 1:2, syncope; 2:4, arrhythmia; 1:3,
hypertension; 1:0, carotid-artery
plaque; 0:5, coronary syndrome, chest
pain, ischemia; 0:4, myocardial
infarction, CABG, death due to
myocardial infarction; 0:5, peripheral
edema; 0:1, stroke; 0:1, heart failure
Kalinchenko,
2010 (11)
35–70 Metabolic syndrome/Y 7.5 Parenteral TU 1000 mg im
at baseline, 6 and
18 wk
71:113 Lipids7 2:0, angina, myocardial infarctiona
Jones, 2011 (10) 40 Type 2 diabetes or
metabolic
syndrome/Y
12 Transdermal gel 60 mg/d 112:108 Lipids7; BP7 12:5b
Ho, 2011 (13) 40 Symptoms of T
deficiency/Y
12 Parenteral TU 1000 mg im
at baseline, 6, 18, 30,
and 48 wk




18–80 Y 6 Transdermal 1.62% gel
2.5 mg/d
40:234 0:11, vascular disorders
Abbreviations: TU, T undecanoate; HDL, high-density lipoprotein; BP, blood pressure; Y, yes; N, no.
a According to report on discontinuation of intervention (Ref. 11, p 606).
b According to safety report (phases 1 and 2) (Ref. 10, p 835).
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pass graft (CABG), thrombosis, cardiovascular com-
plaints, heart failure, chest pain, vascular events, syncope,
stroke, pulmonary embolism, and abdominal aneurysm
(Table 2). The most remarkable study was performed in
209 men 65 years of age or older who had limitations in
mobility and low serum levels of total or free T (7). The
trial was stopped before enrollment had been completed
because of an incidence of adverse cardiovascular events
that was higher in the T group than in the placebo group.
Authors have argued that the generalizability of the data
ofthisstudyaboutthesafetyofTtherapyis limitedbythefact
that cardiovascular eventswere not a preplannedprimaryor
secondaryoutcome,andtherefore,astructuredevaluationof
cardiovascular events was not performed, a factor that may
have influenced the ascertainment of events. Two studies
evaluating specifically the effect of T on atherosclerosis and
arterial stiffness are presently ongoing or recently completed





Chronic heart failure inmen is associatedwith anabolic
hormone depletion, and deficiency of circulating total and
free T, dehydroepiandrosterone sulfate, and IGF-I has
been suggested to be an independentmarker of poor prog-
nosis (93, 94). Trials with T therapy have been conducted
in these patients with chronic heart failure, and a meta-
analysis of 4 such trials indicates a treatment effect on
improved functional capacity (95). An effect of T therapy
onmortality has not been established, but a study onmor-
tality (ClinicalTrials.gov,NCT01377103) is ongoing.An-
other study showed that physiological T replacement re-
duced QT dispersion in a heart failure cohort (96); T
therapyhadno effect on the rhythm in a cohortwith stable
coronary disease (96).
Coronary artery disease
Patients with stable angina have been shown to display
reduced exercise-induced myocardial ischemia after low-
dose supplemental T treatment (8, 97). These findings are
supported by associations of altered androgen status with
ST segment changes (98).
Obstacles and Limitations of
Observational Studies
Assay, time of blood sampling, and the use of
free, bioavailable, and total T
A source of variability in the interpretation of large
epidemiological studies might be the quality of T assay as
well as the time of blood sample collection. T secretion
displays a diurnal variation with highest serum concen-
trations early in the morning in younger men. Blood sam-
ple collection time was identified as a source of heteroge-
neity (P .03) in a reviewonT andmortality (78). Studies
that usedmorning samples (yes vs no) had an estimate RR
(95%CI) of 1.15 (0.94–1.41), and studies that did not use
morning samples had an increased estimate RR (95%CI)
of 1.61 (1.28–2.03) for mortality. The same meta-regres-
sion analysis did not reveal differences according to the
type of T assay (platform-based immunoassay vs gas chro-
matography/tandem mass spectrometry or RIA with ex-
traction) with respect to mortality (78).
Presentation of the data according to total, free, or bio-
available concentrations may also cause confusion in in-
terpretation of the data. First, there are issues as to the
accuracy and comparability of different assay techniques
and calculations used to estimate free and bioavailable T
fractions (99). Second, there are also potential conceptual
issues. For example, data presenting the relationship be-
tween total T and incident diabetes may differ from data
presenting the relationship between free T and incident
diabetes. Data with a statistically significant association
between freeTand incident type2diabetes suggest adirect
sex steroid effect (100), whereas data with total T might
reflect the relationship between SHBG and diabetes; low
SHBG is a strong predictor of diabetes (101). SHBG levels
correlate positively with insulin sensitivity (102), and a
decrease in SHBG is correlated to a decrease in insulin
sensitivity, which is a known feature preceding type 2 di-
abetes. A decrease in insulin sensitivity is also associated
with low-grade systemic inflammation, which precedes
CVD.
Aromatization
The rate of aromatization affects androgen concentra-
tions through strong negative feedback inhibition of go-
nadotropinandTsecretion exertedbyestradiol (103).The
rate of aromatization is higher in oldermen, partly related
to higher percentage fat mass (55).Whether differences in
circulating estradiol concentrations resulting from varia-
tion in aromatizationper se affectCVDneeds to be further
investigated.
Genetic polymorphisms
Genetic polymorphisms in SHBG (104, 105), a poly-
morphism in locus FAM9B on the X-chromosome (104),
and the CAG repeat polymorphism in the AR (106) have
beendescribed that impact on serumTconcentrations.On
the one hand, part of the genetically determined variation
in serum T concentrations may reflect differences in an-
drogen sensitivity and feedback set point (106). On the
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other hand, some of these polymorphisms, aswell as other
genetic variants, may in turn contribute to the between-
subject variation in T effects (107, 108). Thus, genetic
contribution to the variability of T levels and T effects
complicates the interpretation of observational studies.
Confounding
According to studies in legally castrated men and cas-
trated male singers, who appear to have unaltered cardio-
vascular risk profiles and preserved life expectancy, en-
dogenous T does not seem to have particular beneficial or
adverse effects on the cardiovascular system (109, 110).
Unfortunately, results ofmost observational studies of less
healthy males of the general population might be affected
by uncontrollable confounding. A variety of environmen-
tal influences may disturb clear insight into beneficial or
adverse androgen effects on the cardiovascular system.
Confounding may be considered a mixing of effects: the
estimate of the effect of the exposure of interest, T, is
distorted because it is mixed with the effect of an extra-
neous factor (111). Examples of relevant extraneous fac-
tors are smoking, medications, infectious diseases, alco-
hol, and physical activity. Examination of published
prospective studies shows a wide variation in the way ad-
justment for confoundingwas performed (19). In fact, this
item is probably one of the main obstacles to gaining un-
equivocal insight from observation studies, mainly be-
cause not all extraneous factors are confounders; some
factors are in fact involved in the pathogenesis of andro-
gen-related cardiovascular effects. For example, on the
one hand, deterioration of body composition is associated
with low T, and deterioration of body composition is re-
lated to the risk for metabolic syndrome, type 2 diabetes,
and CVD. On the other hand, low T levels might deteri-
orate body composition (112). The question thus is
whether a change in body composition precedes a change
in sex steroid concentrations, or is the converse the case?
Two prospective studies revealed a role of lowT for the
development of the metabolic syndrome and type 2 dia-
betes (100, 113), and one study displayed risk of the pres-
ence ofmetabolic syndrome for lowT (114). In the former
two prospective studies, the baseline bodymass indexwas
already deteriorated (100, 113), suggesting that a change
in body composition precedes a change in sex steroids.
One may also argue that the main portion of an increase
in body mass index will be caused by continuing energy
excess, and that the contribution of sex steroids will prob-
ably be limited. Further arguments for the sequence of
events areprovidedbynormalizationofTafterweight loss
by Roux-en-Y bypass surgery (115) and by the inverse
relationship between Leydig cell T secretion and insulin
resistance (116).Of course, a decrease inTand an increase
in estradiol due to weight gain may by itself accelerate
metabolic dysfunction (46) and may affect the cardiovas-
cular system (58, 117). The relevance of the degree of
aromatization is further illustrated by rare cases of men
with congenital aromatase deficiency. These male sub-
jects, who present with high serum T and low estradiol
display abdominal obesity, early-onset metabolic syn-
drome, dislipidemia, and nonalcoholic fatty liver disease,
with concomitant increased cardiovascular risk (118). Ex-
periments due to these findings suggested a protective role
for estradiol with respect to metabolic disease (119).
Summary
In males of the general population, a growing number of
prospective studies suggest a modest association between
low endogenous T and both incident CVD and cardiovas-
cular mortality. Low endogenous T might be related to
specific events such as thrombosis or arrhythmia, or, be-
cause residual confounding cannot be definitely excluded,
low T may reflect a status of poorer health. In general,
studies do not provide substantial evidence for a relation-
ship between low T and atherosclerosis. Results of pro-
spective studies on atherosclerosis (72–77) and prospec-
tive studies on incident myocardial infarction (79–81)
reveal no unequivocal relationship (19). Trials with ex-
ogenousT therapy report on the occurrence of thrombosis
and arrhythmia, but they are inadequately powered for
CVD events.
One may speculate that potential beneficial effects of
androgens may depend on an “optimal window” of T
concentration, depending on age, degree of aromatiza-
tion, and genetic background, whereas adverse effects
might be expected in concentrations below or above this
optimal window. The hypothesis is supported by adverse
effects inhigh-normal to supraphysiological androgen lev-
els, as sometimes used by athletes (51, 56, 69), as well as
by low androgen levels and its risk for osteoporosis (17),
and extremely low or absent aromatization and risk for
metabolicdiseases (118,119).Dose-response trials oncar-
diovascular outcomes such as arrhythmias, eg, along the
same lines as has been performed for the study of T effects
on body composition (120), may shed some light on this
issue. So far, treatment with T to restore T concentrations
to this optimal window have not been proven to be ben-
eficial with respect to CVD. Nevertheless, males with low
T and specific cardiovascular conditions, eg, heart failure
or coronary artery disease, may benefit from substitution
therapy. A cautious, restrained approach to T therapy in
aging men is advisable, pending clarification of benefits
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and risks byadequately powered clinical trials of sufficient
duration.
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